Goldman Sachs Group Inc. Has $7.91 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Goldman Sachs Group Inc. reduced its holdings in Recursion Pharmaceuticals by 24.4%, selling 481,645 shares; the fund owns 1,495,863 shares valued at approximately $7.91 million.
• Research analysts have mixed views on Recursion Pharmaceuticals, with Needham & Company maintaining a "buy" rating and a target price of $8.00, while Morgan Stanley set an "equal weight" rating with a target price of $5.00.
• Recursion Pharmaceuticals reported quarterly earnings with EPS of ($0.41), missing estimates but achieving a revenue of $19.10 million, which was above the consensus of $15.38 million.

Goldman Sachs Group Inc. lessened its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 24.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,495,863 shares of the company's stock after selling 481,645 shares during the period. Goldman Sachs Group Inc. owned 0.37% of Recursion Pharmaceuticals worth $7,913,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RXRX. AlphaQuest LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth $36,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after acquiring an additional 2,026 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth $54,000. San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth $54,000. Finally, ADG Wealth Management Group LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth $55,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on RXRX shares. Needham & Company LLC reissued a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $7.25.

Insider Activity

In related news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the sale, the insider owned 668,197 shares of the company's stock, valued at $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 8.43% of the company's stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $4.83 on Friday. The firm's 50-day moving average is $5.34 and its 200-day moving average is $5.30. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -2.71 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The business's revenue for the quarter was up 33.3% compared to the same quarter last year. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.